Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Alteplase→

Alteplase Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
105857-23-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
Recombinant tissue-type plasminogen activator (rt-PA)fibrinolytic thrombolytic agent
Mechanism of action
A serine protease that catalyses conversion of plasminogen to plasmin. Activation is enhanced in the presence of fibrin, promoting degradation of fibrin-rich thrombi.
Indications / reported uses
  • Acute ischaemic stroke in appropriately selected patients within the product-specific treatment window
  • Acute myocardial infarction and acute massive pulmonary embolism in selected clinical settings
  • Restoration of function to central venous access devices occluded by thrombus with the low-dose catheter-lock formulation; indications and dosing are formulation-specific

Sources: US DailyMed — Activase (alteplase) · US FDA prescribing information — Activase · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Alteplase Environmental Risk Assessment (ERA) (the Alteplase ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.